Meeting
2022 ASCO Annual Meeting
A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.
Authors
Geoffrey Thomas Gibney
Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC
Geoffrey Thomas Gibney , Sandra J. Lee , Michael B. Atkins , Terence Z. Wong , Jennifer Guerriero , Thomas Urban Marron , Gary Irvin Cohen , Thach-Giao Truong , Richard D. Carvajal , Bradley Snyder , Michael Farwell , John M. Kirkwood , Jedd D. Wolchok
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04462406
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9591)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9591
Abstract #
TPS9591
Poster Bd #
183a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.
First Author: Heather L. McArthur
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2016 ASCO Annual Meeting
Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.
First Author: Yousef Zakharia